(Adds that CVS plans to dispense mifepristone)
By Brendan Pierson
Jan 5 (Reuters) – The U.S. Food and Drug Administration on Tuesday finalized a rule allowing mifepristone, one of two drugs used in medication abortions, to be dispensed by retail pharmacies. The rule will make medication abortion, which accounts for more than half of U.S. abortions, more accessible in states where abortion remains legal, but its impact in states that have banned abortion will be limited.
WHAT CHANGES FOR PATIENTS UNDER THE NEW RULE?
Patients will be able to get the drug more quickly.
Previously, mifepristone had to be dispensed by an authorized clinic or through certain specialty mail-order pharmacies — a process that could take days or even weeks if a clinic is busy.
Once pharmacies begin dispensing the drug in states that allow abortion, it "will make it much easier to access the pill," according to Naomi Cahn, a professor at University of Virginia School of Law.
WHAT DOES NOT CHANGE?
All patients still need a prescription to get mifepristone. It will not be available over the counter.
Most significantly, the FDA's new regulation will not help patients get abortion pills in states that have banned abortion, said Amanda Allen of the Lawyering Project, a legal group that defends abortion rights.
Nonetheless, Allen said, the rule could make it easier to travel out of state for a medication abortion. Currently, a patient seeking a medication abortion in another state must both obtain the prescription and the pill in that state. That will become much easier if the pill can be picked up at a retail pharmacy, she said.
As of November, 16 states that permit some abortions had laws restricting mifepristone, including requirements that it be provided by a physician, according to the Kaiser Family Foundation. It is not clear whether pharmacies must comply with these laws; some legal scholars have argued that federal rules should override them, but the issue has not been tested in court.
HOW LONG BEFORE MIFEPRISTONE IS AVAILABLE IN PHARMACIES?
It is not yet clear, because pharmacies must first be certified by one of the drug's manufacturers to dispense it in accordance with federal safety rules.
Walgreens Boots Alliance and CVS Health both said that they plan to begin dispensing the pill. Rite Aid Corp said it was reviewing the new rule and intended to comply with federal and state law but has not yet confirmed that it plans to dispense the drug.
COULD THE NEW REGULATION FACE LEGAL CHALLENGES?
Yes. Anti-abortion groups represented by the conservative legal group Alliance Defending Freedom already filed a lawsuit in November seeking to undo the FDA's approval of mifepristone for abortion entirely on alleged safety grounds.
If the Trump-appointed judge rules in favor of suspending the FDA's 20-year-old approval of the drug, it would effectively pull the drug from the market nationwide and render the latest FDA rule moot.
The judge, Matthew Kacsmaryk, has been friendly to conservative causes before, previously ruling against the Biden administration in a case over healthcare coverage for transgender people and in a separate case ordering it to reinstate a Trump-era immigration policy requiring asylum seekers to wait in Mexico.
Alliance Defending Freedom senior counsel Julie Blake said in a statement that the new rule "just bolsters the strength and importance of our case."
COULD ANTI-ABORTION STATES TAKE FURTHER STEPS TO RESTRICT MEDICATION ABORTION?
Some conservative policy groups and lawmakers have proposed laws that would make it a crime to help someone travel to another state for abortion or mail them abortion pills.
Experts have said there would be little if any direct precedent for whether such laws would be enforceable, potentially triggering a new round of legal battles.
(Reporting by Brendan Pierson in New York, Editing by Alexia Garamfalvi and Lisa Shumaker)
An internal investigation by the Greenville Police Department found that the four officers "exercised restraint" at the June abortion rights protest.
LeMahieu's comments mark the first time a leader of the Senate Republicans has shown support for the idea.
FTAI Aviation Ltd. ( NASDAQ:FTAI ), might not be a large cap stock, but it received a lot of attention from a…
Medicare won’t pay for the drug unless patients are enrolled in government-sanctioned trials—and no such studies are under way or planned.
Two in five Americans are obese. Treatments that target obesity directly could be the next blockbuster pharma category.
After all, many currently well-established companies were once small- or mid-cap stocks. Axsome Therapeutics is a mid-cap drugmaker coming off a solid performance in 2022, during which its shares more than doubled. The company could carry this momentum into this year.
Atai Life Sciences (NASDAQ: ATAI)-owned Perception Neuroscience announced that the Phase 2a trial of PCN-101 (R-ketamine) did not meet its primary endpoint of a statistically significant change from baseline in participants' MADRS (Montgomery-Åsberg Depression Rating Scale) score at 24 hours compared to placebo. MADRS is a widely used clinician‐rated measure of depressive severity. The Phase 2a proof-of-concept trial was a two-week, randomized, double-blind, placebo-controlled multi-center study
(Bloomberg) — US inflation data in the coming week are expected to stay consistent with a gradual step-down in cost pressures, and will help determine the size of the Federal Reserve’s next interest-rate increase.Most Read from BloombergThailand Brings Back Covid Entry Rules as China’s Borders ReopenMcCarthy’s Speaker Deal Could Stymie Defense Spending Next YearTrump’s Troubles Mount as Special Counsel Gets New 2020 EvidenceThe 6 Republicans Who Switched Their Votes to Make McCarthy House Speak
The past three years have been significant for pharma giant Pfizer (NYSE: PFE) and its shareholders. For instance, Pfizer's shares remain reasonably valued. There are more reasons to buy Pfizer's shares, especially at current levels.
E-commerce billionaire Jack Ma will give up control of Ant Group, the leading Chinese financial technology provider he founded.
With rates rising, biotech has faded. Investors have favored the pharma stalwarts. Bank of America’s drug analyst Geoff Meacham runs through the one’s to watch and a few to avoid. Plus: Could it be another banner year for Devon Energy?
Of the 66 million Americans who receive a Social Security check every month, according to the Social Security Administration, one couple claiming benefits may come as a surprise: President Joe Biden…
Successful clinical trial results recently pushed this stock more than 68% higher overnight — but what about the road ahead?
A distinct puncture hole on a fleshy right forearm, seen just inside the sleeve of a boxy Mao suit. This tiny mark, when first spotted on Kim Jong-un in May 2020, caused an instant reaction among observers of the North Korean regime. Was it the trace of an IV drip? A giveaway of surgery? At the very least, it was an unusual sign of vulnerability in a man who rules his nation with a suffocating grasp.
Biotechs that utilize gene editing — a set of techniques allowing scientists to modify an organism's DNA — have the potential to help revolutionize medicine by developing innovative treatments for otherwise incurable illnesses. Let's consider two biotechs looking to make use of gene editing to develop breakthrough therapies: CRISPR Therapeutics (NASDAQ: CRSP) and Sarepta Therapeutics (NASDAQ: SRPT).
The FDA accepts and grants priority review to Roche's (RHHBY) biologics license application for glofitamab to treat relapsed or refractory large B-cell lymphoma. The decision is due on Jul 1, 2023.
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
Axsome Therapeutics (NASDAQ: AXSM) soared more than 100%. Vertex submitted a potential blockbuster in a new treatment area to regulators. Let's check out why Axsome and Vertex are still stocks to buy.
Gov. Ron DeSantis declared a state of emergency Friday and called out the state National Guard as the arrival of hundreds of Cuban and Haitian migrants in South Florida overwhelmed local authorities and raised fears of a major migration event.
In November, nearly 66 million Americans, many of whom are aged 62 and over, received a Social Security benefit. President Joe Biden believes he has the solution that can resolve what ails Social Security, but he's going to need the help of newly elected lawmakers to fix it. For each of the past 83 years, the Social Security Board of Trustees has released a report that's examined the financial status of the program over the short term (the next 10 years) and long term (75 years following the release of a report).
